Survival Outcomes of Different Treatments for Low-Grade Endometrial Stromal Sarcoma: What Patients and Doctors Need to Know
For women diagnosed with low-grade endometrial stromal sarcoma (LGESS)—a rare, slow-growing type of uterine cancer—choosing the right treatment can feel like navigating uncharted territory. Unlike more aggressive cancers, LGESS responds well to hormone therapy, but surgery, radiation, and chemotherapy are also options. Until recently, there was little clear data on which combination of treatments offers the best long-term survival. A 2019 study published in the Chinese Medical Journal is changing that, providing real-world insights into how different therapies impact outcomes for this understudied disease.
LGESS originates in the connective tissue of the uterus and grows slowly, but it still requires proactive management. It’s hormone-sensitive—meaning it relies on estrogen or progesterone to grow—so hormone therapy is a key player. However, surgery to remove the uterus (hysterectomy) is often the first step. The question has always been: What comes next? Do radiation, hormone therapy, or chemotherapy add value to surgery alone?
To find answers, researchers Wang M, Meng SH, Li B, He Y, and Wu YM analyzed data from 208 patients with LGESS treated at hospitals in China between 2000 and 2015. They compared survival rates across four treatment approaches: surgery alone, surgery plus hormone therapy, surgery plus radiation, and surgery plus chemotherapy. They also looked at factors like tumor stage, age, and whether the ovaries were preserved.
The Key Findings
The study’s results offer clear guidance for both patients and doctors:
- Surgery is the foundation: A total hysterectomy (with or without removing the ovaries) was linked to an 89% 5-year survival rate. For patients who had complete surgery (no remaining cancer cells), survival was even higher—reinforcing that removing as much of the tumor as possible is critical.
- Hormone therapy boosts survival: Adding hormone therapy (such as progestins like medroxyprogesterone acetate or aromatase inhibitors) improved 5-year survival to 95%. This was especially true for patients with advanced disease (stage III/IV) or those who couldn’t have complete surgery. Hormone therapy targets the cancer’s hormone dependence, stopping residual cells from growing.
- Radiation has limited benefit: Adjuvant radiation (given after surgery to kill leftover cells) did not improve overall survival. It may help control local recurrence (cancer coming back in the uterus), but it’s not a routine solution for everyone.
- Chemotherapy isn’t helpful: Few patients received chemotherapy, and it did not improve survival in this group. This aligns with other research showing that LGESS rarely responds to traditional chemotherapy.
How These Results Fit With Existing Research
The findings aren’t just new—they confirm what smaller studies have suggested:
- A 2012 review in Annals of Oncology (Reichardt P) highlighted hormone therapy as a cornerstone of LGESS treatment because of the cancer’s hormone sensitivity.
- A 2011 study in Gynecologic Oncology (Dos Santos LA et al.) found that lymph node metastasis is rare in LGESS (only 5–10% of cases), so removing lymph nodes may not be necessary for all patients—supporting the current study’s finding that lymph node dissection didn’t impact survival.
- The Rare Cancer Network (Schick U et al., 2012) also identified complete surgery and tumor stage as key prognostic factors, which the current study echoes.
For young women with LGESS, ovarian conservation is another important consideration. A 2017 study in Obstetrics & Gynecology (Matsuo K et al.) found that preserving ovaries in early-stage gynecologic cancer doesn’t hurt survival—and the current study backs this up: ovary removal didn’t improve outcomes for premenopausal patients.
What This Means for Patients and Doctors
For clinicians, the takeaway is straightforward: Prioritize complete surgery first, then use hormone therapy to target residual cancer cells. Radiation should be reserved for patients at high risk of local recurrence, not as a routine add-on. For patients, this data offers clarity: Hormone therapy isn’t just for “advanced” cases—it can be a life-saving addition to surgery even for early-stage LGESS.
Like all retrospective studies (which rely on existing medical records), this research has limitations. The sample size is modest, and results may not apply to all populations. More prospective trials (where patients are randomly assigned to treatments) are needed to confirm these findings. However, the study’s real-world data is invaluable for a rare cancer like LGESS, where large trials are hard to run.
The Bottom Line
For women with LGESS, this study is a beacon of hope. It confirms that LGESS is manageable with personalized care: Surgery to remove the tumor, followed by hormone therapy to keep remaining cells in check. Radiation and chemotherapy play smaller roles—if any.
The National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program notes that LGESS accounts for just 1–2% of uterine cancers, so every study adds critical knowledge. This research moves the needle, giving patients and doctors the data they need to make informed decisions.
If you or a loved one has LGESS, talk to your doctor about how these findings apply to your case. Remember: LGESS is slow-growing, and with the right treatment, long-term survival is achievable.
References
Wang M, Meng SH, Li B, He Y, Wu YM. Survival outcomes of different treatment modalities in patients with low-grade endometrial stromal sarcoma. Chinese Medical Journal 2019;132:1128–1132. doi.org/10.1097/CM9.0000000000000259
Reichardt P. The treatment of uterine sarcomas. Annals of Oncology 2012;23(Suppl 10):x151–x157. doi.org/10.1093/annonc/mds359
Thanopoulou E, Judson I. Hormonal therapy in gynecological sarcomas. Expert Review of Anticancer Therapy 2012;12:885–894. doi.org/10.1586/era.12.74
Dos Santos LA, Garg K, Diaz JP, Soslow RA, Hensley ML, Alektiar KM, et al. Incidence of lymph node and adnexal metastasis in endometrial stromal sarcoma. Gynecologic Oncology 2011;121:319–322. doi.org/10.1016/j.ygyno.2010.12.363
Schick U, Bolukbasi Y, Thariat J, Abdahbortnyak R, Kuten A, Igdem S, et al. Outcome and prognostic factors in endometrial stromal tumors: a Rare Cancer Network study. International Journal of Radiation Oncology Biology Physics 2012;82:e757–e763. doi.org/10.1016/j.ijrobp.2011.11.005
Matsuo K, Machida H, Shoupe D, Melamed A, Muderspach LI, Roman LD, et al. Ovarian conservation and overall survival in young women with early-stage cervical cancer. Obstetrics & Gynecology 2017;129:139–151. doi.org/10.1097/AOG.0000000000001754
National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer statistics. Available from: seer.cancer.gov. [Accessed November 16, 2017]
Was this helpful?
0 / 0